diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5714diaendo-5714Research ArticleСтатьиArticlesРоль фенофибрата в лечении микрососудистых осложнений сахарного диабета 2 типаThe role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitusКошельЛариса ВикторовнаKoshel'Larisa Viktorovna-РоманцоваТатьяна ИвановнаRomantsovaTatiana Ivanovnaromantsovatatiana@rambler.ruГОУ ВПО Московская медицинская акдемия им. И.М. Сеченова, МоскваI.M. Sechenov Moscow Medical Academy, Moscow200915122009124№4 (2009)99103Copyright © Кошель Л.В., Романцова Т.И., 20092009Кошель Л.В., Романцова Т.И.Koshel' L.V., Romantsova T.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5714

Результаты многочисленных исследований убедительно доказывают, что фенофибрат, влияя на активность рецепторов PPAR-?, ока-зывает гиполипидемическое, противовоспалительное и антиоксидантное действие. Активация рецепторов PPAR-? в печени приводитк снижению уровня липидов, вызывающих атеросклероз (ЛПОНП, мелкие плотные ЛПНП), и повышению уровня антиатерогенныхЛПВП. Активация рецепторов PPAR-? в клетках сосудов позволяет снизить активность маркеров воспаления, таких как С-реактив-ный белок, фактор некроза опухоли-?, интерлейкин-6, фибриноген и др. Эти преимущества в конечном итоге снижают риск развитияи прогрессирования макро- и микрососудистых осложнений при СД.

Results of numerous studies give definitive evidence that phenofibrate affects activity of PPAR-a receptors in liver and thereby decreases the level oflipids responsible for the development of atherosclerosis (VLDL, small dense LDL); simultaneously, it increases the level of anti-atherogenic HDL.Activation of PPAR-a receptors in vascular cells decreases activity of inflammation markers, such as C-reactive protein, TNF-a, IL-6, fibrinogen,etc. These effects of phenofibrate eventually lead to reduced risk of macro- and microvascular diabetic complications.

фенофибратретинопатиянефропатиянейропатиясахарный диабетphenofibrateretinopathyneuropathydiabetes mellitusReferencesKeech A.C., Mitchell P., Summanen P. A. еt al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial //Lancet. - 2007. - 370. - P. 1687-1697.Keech A.C., Mitchell P., Summanen P. A. еt al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial //Lancet. - 2007. - 370. - P. 1687-1697.Fruchart J.C., Respe E., Lefebvre A.M., et al. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid via PPARalpha activation //J. Lipid Res. - 1999. - 40(11). - P. 2099-2110.Fruchart J.C., Respe E., Lefebvre A.M., et al. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid via PPARalpha activation //J. Lipid Res. - 1999. - 40(11). - P. 2099-2110.Chapman M.G. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives //Atherosclerosis. - 2003. - 171. - P. 1-13.Chapman M.G. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives //Atherosclerosis. - 2003. - 171. - P. 1-13.Plutzky J. PPARs as therapeutic targets: reverse ardiology? //Science. - 2003. - 302. - P. 406-07.Plutzky J. PPARs as therapeutic targets: reverse ardiology? //Science. - 2003. - 302. - P. 406-07.Ziozenkova O., Perrey S., Asatryan L., at al. Lipolysis of triglyceridrich lipoproteins generates PPAR ligands: evidence for an anti-inflammatory role for lipoprotein lipase // Proc. Natl. Acad. Sci. USA. - 2003. - 100. - P. 2730-2735.Ziozenkova O., Perrey S., Asatryan L., at al. Lipolysis of triglyceridrich lipoproteins generates PPAR ligands: evidence for an anti-inflammatory role for lipoprotein lipase // Proc. Natl. Acad. Sci. USA. - 2003. - 100. - P. 2730-2735.Marx N., Kehrle B., Kohlhammer K., at al. PPAR activators as anti-inflammatory mediators in human T lymphocytes. Implications for atherosclerosis and transplantation-associated arteriosclerosis// Circ. Res. - 2002. - 90. - P. 703-710.Marx N., Kehrle B., Kohlhammer K., at al. PPAR activators as anti-inflammatory mediators in human T lymphocytes. Implications for atherosclerosis and transplantation-associated arteriosclerosis// Circ. Res. - 2002. - 90. - P. 703-710.Brownlee M., Banting Lecture 2004. The pathobiology of diabetic complications. A unifyingmechanism //Diabetes. - 2005. - 54. - P. 1615-1625.Brownlee M., Banting Lecture 2004. The pathobiology of diabetic complications. A unifyingmechanism //Diabetes. - 2005. - 54. - P. 1615-1625.Chew E.Y., Klein M.L., Ferris F.L. еt al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. ETDRS Report 22 //Arch. Ophthalmol. - 1996. - 114. - P. 1097-84.Chew E.Y., Klein M.L., Ferris F.L. еt al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. ETDRS Report 22 //Arch. Ophthalmol. - 1996. - 114. - P. 1097-84.Thomas M.С. Serum lipids and the progression of nephropathy in type 1 diabetes // Diabetes care. - 2006. - 29 (2). - P. 317-322.Thomas M.С. Serum lipids and the progression of nephropathy in type 1 diabetes // Diabetes care. - 2006. - 29 (2). - P. 317-322.Keating G.M., Croom K.F. Fenofibrate. A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes mellitus. Drugs 2007; 67(1); 121-153.Keating G.M., Croom K.F. Fenofibrate. A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes mellitus. Drugs 2007; 67(1); 121-153.Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.Lyons T.J., Jenrins A.J., Zheng D. et.al. Diabetic retinopathy and serumlipoprotein subclasses in the DCCT/EDIC cohort //Invest. Ophthalmol. Vis. Sci. - 2004. - 45. - P. 910-8.Lyons T.J., Jenrins A.J., Zheng D. et.al. Diabetic retinopathy and serumlipoprotein subclasses in the DCCT/EDIC cohort //Invest. Ophthalmol. Vis. Sci. - 2004. - 45. - P. 910-8.Kaysen G.A., Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction //J. Am. Soc. Nephrol. - 2004. - 15. - P. 538-548.Kaysen G.A., Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction //J. Am. Soc. Nephrol. - 2004. - 15. - P. 538-548.Keech A., Simes R.J., Barter P. et.al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial // Lancet. - 2005. - 26. - P. 1849-61.Keech A., Simes R.J., Barter P. et.al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial // Lancet. - 2005. - 26. - P. 1849-61.Rajamani K., Colman P. G., Best J.D. et.al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (the FIELD study): a prespecified analysis of randomized controlled trial // Lancet. - 2009. - 373. - P. 1780-1788.Rajamani K., Colman P. G., Best J.D. et.al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (the FIELD study): a prespecified analysis of randomized controlled trial // Lancet. - 2009. - 373. - P. 1780-1788.Ansquer J.C., Foucher C., Rattier S. et.al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) // Am. J. Kidney Dis. - 2005. - 45. - P. 485-493.Ansquer J.C., Foucher C., Rattier S. et.al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) // Am. J. Kidney Dis. - 2005. - 45. - P. 485-493.Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis //Am. J. Physiol. 2001, 280: P. 1358-66.Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis //Am. J. Physiol. 2001, 280: P. 1358-66.Kim J., Aim J.H., Kim J.H. et.al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway // ExP. Eye. Res. - 2007. - 84. - P. 886-893.Kim J., Aim J.H., Kim J.H. et.al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway // ExP. Eye. Res. - 2007. - 84. - P. 886-893.Malic J., Melenovsky V., Widilerle D. et.al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial - FAT) //Cardiovasc. Res. - 2001. - 52. - P. 290-298.Malic J., Melenovsky V., Widilerle D. et.al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial - FAT) //Cardiovasc. Res. - 2001. - 52. - P. 290-298.Demircan N., Safran B.G., Soylu M. et.al. Determination of vitreus interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy// Eye. - 2006. - 20. - P. 1366-1369.Demircan N., Safran B.G., Soylu M. et.al. Determination of vitreus interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy// Eye. - 2006. - 20. - P. 1366-1369.Ryan K.E., McCance D.R., Powell L. et.al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men //Atherosclerosis. - 2006. - 194. - P. 123-130.Ryan K.E., McCance D.R., Powell L. et.al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men //Atherosclerosis. - 2006. - 194. - P. 123-130.Losada M., Alio J.L. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy //Doc. Ophthalmol. - 1997. - 93. - P. 223-229.Losada M., Alio J.L. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy //Doc. Ophthalmol. - 1997. - 93. - P. 223-229.Chen L., Zhang J., Zhang Y. Improvement of inflammatory responses associated with NF-kappaB pathway in kidneys from diabetic rats //Inflamma. Res. - 2008. - 57. - P. 199-204.Chen L., Zhang J., Zhang Y. Improvement of inflammatory responses associated with NF-kappaB pathway in kidneys from diabetic rats //Inflamma. Res. - 2008. - 57. - P. 199-204.Park C.W., Zhang Y., Zhang X. et.al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice //Kidney Int. - 2006. - 69. - P. 1511-1517.Park C.W., Zhang Y., Zhang X. et.al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice //Kidney Int. - 2006. - 69. - P. 1511-1517.Ganessaratem K. Balendiran, Balakrishnan Rajkumar. Fibrates inhibit aldose reductase activity in the forward and reverse reactions //Biochemical Pharmacology. - 2005. - 70. - P. 1653-1663.Ganessaratem K. Balendiran, Balakrishnan Rajkumar. Fibrates inhibit aldose reductase activity in the forward and reverse reactions //Biochemical Pharmacology. - 2005. - 70. - P. 1653-1663.Дедов И.И., Шестакова М.В. Сахарный диабет. М., 2003.Дедов И.И., Шестакова М.В. Сахарный диабет. М., 2003.Maison P. , Mennen L., Sapinho D., et.al. A pharmacoepidemical assessment of the effect of statins and fibrates on fibrinogen concentration // Atherosclerosis. - 2002. - 160 (1). - P. 155-160.Maison P. , Mennen L., Sapinho D., et.al. A pharmacoepidemical assessment of the effect of statins and fibrates on fibrinogen concentration // Atherosclerosis. - 2002. - 160 (1). - P. 155-160.Fujisawa T., Ikegami H., Yamato E. et.al. Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in type 2 diabetes mellitus //Diabet. Med. - 1999. - 16. - P. 522-526.Fujisawa T., Ikegami H., Yamato E. et.al. Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in type 2 diabetes mellitus //Diabet. Med. - 1999. - 16. - P. 522-526.

The authors declare that there are no conflicts of interest present.